Abeona Therapeutics Inc vs Msci Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Msci Inc trades at $562 (market cap $40.84B). The key difference: Msci Inc is far larger — about 97× Abeona Therapeutics Inc's market cap, and Msci Inc pays a 1.46% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MSCI | |
|---|---|---|
Market Cap | $421.19M | $40.84B |
Sector | Health | Financials |
52-Week High | $7.45 | $643.83 |
52-Week Low | $4.17 | $511.84 |
Enterprise Value | $276.10M | $47.00B |
Dividend Yield | — | 1.46% |
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →